Αρχική World News FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder... World News FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer Από Ogkologos - 8 Ιουλίου, 2026 250 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the POTOMAC study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR ESMO Advocates for EU Legislation to Prevent Oncologist Burnout and Ensure... 23 Ιουνίου, 2025 Can Using Essential Oils Help Treat Cancer and Its Side Effects? 13 Ιουλίου, 2021 Arsenic Trioxide in Combination with All-Trans Retinoic Acid for the Treatment... 3 Σεπτεμβρίου, 2025 Alcohol linked to more than 740,000 new cancer cases globally in... 14 Ιουλίου, 2021 Φόρτωση περισσοτέρων HOT NEWS Cannabis, cannabinoids and cancer – the evidence so far Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού; Adding Pembrolizumab to Platinum-Based Chemotherapy Improves Survival in Patients with Previously... A new IARC live webinar on evidence in primary cancer prevention